Researchers discover new way to treat deadly childhood brain cancer

February 20, 2014 by Katie Babcock

(Medical Xpress)—Researchers from the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP) have discovered a new way to effectively target a previously difficult-to-treat form of childhood brain cancer called ependymoma.

Professor Michael Taylor (MD,PhD, FRCSC), along with lead author Stephen Mack and co-authors including LMP Prof. Peter Dirks (MD, PhD), published the groundbreaking findings in Nature on February 19, 2014. Their research showed that , the packaging of DNA, is the main cause of this cancer and can be targeted by FDA approved drugs.

DNA code is comparable to a three-billion letter long set of instructions on how a cell should operate. In this analogy, the majority of cancers are caused by words that are misspelled, words that are added or deleted or entire book chapters that are added or deleted.

"When we look at ependymoma, we don't find any misspelled words, deleted or duplicated words or book chapters that are missing. Instead, what we find is that the entire novel is written in the wrong font and the DNA is packaged improperly," said Prof. Taylor. "While epigenetics has been known to play a role in cancer, this is the first time that epigenetics is the prime driver of cancer."

Receiving a diagnosis of ependymoma, the third most common type of childhood , can be devastating. While babies and toddlers are treated with surgery and radiation therapy, chemotherapy has been ineffective and the cancer often recurs.

Impressively, there are already FDA approved drugs that can alter the cancer's epigenetics. "Usually when you make a discovery you have to make a new drug, but there are already drugs that change the font. In this case, there are drugs that are the Microsoft Word equivalent of select all and switch to Times New Roman," said Prof. Taylor.

The team's success relied heavily on their ability to grow and study cells from these rare tumours. Once a patient's tumour is removed from the operating room, its cells are taken to Prof. Peter Dirks's lab to be grown in specialized conditions. The process is so efficient that by the time a child has recovered from surgery, the team has tested the cells and will know whether a specific drug will work.

"I think that's where this project has been so exciting. Dr. Taylor and Steve Mack made a foundational discovery in this tumour, and we were able to bring our expertise together in growing these live cells to see whether targeting this packaging really had any promise," said Prof. Dirks.

The team is optimistic that this will provide hope for children suffering from . Prof. Taylor explains, "We hope it will be an effective treatment. One drug doesn't usually result in a cure, but there are multiple drugs that attack the same mechanism. Even if we can't cure it, we could use the drug to keep it to a treatable disease like diabetes."

If the group receives funding, it could take only three to five years to complete a clinical trial.

Explore further: New prostate cancer drugs may not be targeting root cause of disease, scientists warn

More information: Paper: Epigenomic alterations define lethal CIMP-positive ependymomas of infancy, DOI: 10.1038/nature13108

Related Stories

New prostate cancer drugs may not be targeting root cause of disease, scientists warn

January 27, 2014
(Medical Xpress)—New drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published today (Friday, 24 January 2014) in Cell Death & Differentiation.

Gene sequencing project discovers common driver of a childhood brain tumor

February 19, 2014
The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration ...

Breast cancer researchers find new drug target companion prognostic test for hormone therapy resistance

April 1, 2013
A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive ...

BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy

October 30, 2013
A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and relapse of cancer. The findings are published online in Volume ...

Laboratory detective work points to potential therapy for rare, drug-resistant cancer

February 13, 2014
University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.

Potential brain tumour drug can distinguish cancer cells from healthy ones

October 31, 2013
A potential new drug, already in clinical development, can stop brain tumour cells growing while leaving healthy cells alone, according to new research published today (Wednesday) in PLOS ONE.

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.